This capacity to simultaneously combat tumor progression and protect normal tissues positions morin as a versatile therapeutic candidate
In preclinical animal models: wound closure accelerated (50% closure day 5 vs vehicle day 7, full-thickness excisional model), tendon tensile strength improved (+58% at day 14 vs vehicle, Achilles model), gastric lesion index reduced (6878% vs vehicle, ethanol ulcer model), inflammatory cytokines reduced (TNF- 4252%, IL-6 3844%, colitis model), angiogenesis stimulated (CD31+ MVD +44% vs vehicle), and neuroprotection demonstrated (NSS improved, lesion volume 2834%, TBI model)
A.IsupovM
Hours: 8 AM - 8 PM (Mobile Only) We accept cash and all major credit cards
Ideal candidates typically include adults over 30 experiencing difficulty losing abdominal fat, individuals who have plateaued in their weight loss journey, and those seeking to optimize body composition without the risks associated with full growth hormone therapy